Cardiac metabolism - a promising therapeutic target for heart failure by Noordali, Hannah et al.
 
 
Cardiac metabolism - a promising therapeutic target
for heart failure
Noordali, Hannah; Loudon, Brodie; Frenneaux, Michael; Madhani, Melanie
DOI:
10.1016/j.pharmthera.2017.08.001
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Noordali, H, Loudon, B, Frenneaux, M & Madhani, M 2017, 'Cardiac metabolism - a promising therapeutic target
for heart failure', Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2017.08.001
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
1 
Cardiac metabolism – A promising therapeutic target for heart failure 
 
Hannah Noordalia, Brodie L Loudonb, Michael P Frenneauxb, and Melanie Madhania 
a Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK 
b Norwich Medical School, University of East Anglia, Norwich, UK 
 
 
Address for Correspondence:  
Dr Melanie Madhani (Corresponding Author) 
Institute of Cardiovascular Sciences  
College of Medical and Dental Sciences 
University of Birmingham 
Edgbaston, Birmingham B15 2TT 
 
Tel: 0121 414 6897  
Email: M.Madhani@bham.ac.uk  
  
2 
Abstract  
Both heart failure with reduced ejection fraction (HFrEF) and with preserved ejection 
fraction (HFpEF) are associated with high morbidity and mortality. Although many 
established pharmacological interventions exist for HFrEF, hospitalization and death rates 
remain high, and for those with HFpEF (approximately half of all heart failure patients), 
there are no effective therapies.  Recently, the role of impaired cardiac energetic status in 
heart failure has gained increasing recognition with the identification of reduced capacity 
for both fatty acid and carbohydrate oxidation, impaired function of the electron transport 
chain, reduced capacity to transfer ATP to the cytosol, and inefficient utilization of the 
energy produced. These nodes in the genesis of cardiac energetic impairment provide 
potential therapeutic targets, and there is promising data from recent experimental and 
early-phase clinical studies evaluating modulators such as carnitine palmitoyltransferase 1 
inhibitors, partial fatty acid oxidation inhibitors and mitochondrial-targeted antioxidants. 
Metabolic modulation may provide significant symptomatic and prognostic benefit for 
patients suffering from heart failure above and beyond guideline-directed therapy, but 
further clinical trials are needed.  
 
 
 
 
Keywords:  
Cardiac metabolism; Heart failure; Heart failure with reduced ejection fraction (HFrEF); 
Heart failure with preserved ejection fraction (HFpEF); Metabolic modulation 
3 
Table of Contents 
1. Introduction ................................................................................................................... 6 
2. The Pathophysiology of Heart Failure ............................................................................. 8 
3. Cardiac Metabolism and Energetic Status in the Normal Heart and in Heart Failure ..... 15 
4. Metabolic Modulators: Promising Therapeutic Agents ................................................. 30 
5. Conclusion .................................................................................................................... 50 
Conflict of Interest Statement .......................................................................................... 51 
References........................................................................................................................ 54 
 
 
 
 
 
 
 
Figures:  
Figure 1: An Overview of Cardiac Metabolism in the Healthy Heart .................................. 52 
Figure 2: An Overview of Cardiac Metabolism in the Failing Heart and Targets of Metabolic 
Modulators....................................................................................................................... 53 
 
Table 1: Metabolic modulator clinical status …………………………………………………………………56  
4 
Abbreviations 
ACE  Angiotensin converting enzyme 
ADP  Adenosine diphosphate 
ATP  Adenosine triphosphate 
BNP  Brain natriuretic peptide  
cGMP  cyclic guanosine monophosphate 
CK  Creatine kinase 
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CoA  Coenzyme A 
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CPT  Carnitine palmitoyltransferase 
DCA  Dichloroacetate 
ETC  Electron transport chain 
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HF  Heart failure 
HFpEF  Heart failure with preserved ejection fraction 
HFrEF  Heart failure with reduced ejection fraction 
LVEF  Left ventricular ejection fraction 
MCD  Malonyl-CoA decarboxylase 
NADH  Nicotinamide adenine dinucleotide 
NO  Nitric oxide 
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RAAS  Renin-angiotensin-aldosterone-system 
ROS  Reactive oxygen species 
SS31  Szeto-Schiller peptide 31 
TAC  Transverse aortic constriction 
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1. Introduction 
Chronic heart failure (HF) is a highly prevalent, multi-system disorder, which affects over 23 
million people worldwide (Bui, et al., 2011). The cardiovascular system ensures that blood 
supply matches the metabolic demands of the body. In HF, the reserve of the cardiovascular 
system is overwhelmed due to dysfunction of the cardiac muscle, which is characterized by 
defects in ventricular active- and passive-filling, and contraction. In milder cases, this 
impairment may only be present on exertion, when contractile and filling reserve are 
recruited to increase cardiac output (CO), but in more severe cases, CO may be insufficient 
even at rest. The HF syndrome may occur secondary to a range of cardiovascular insults, 
including myocardial infarction and chronic arterial hypertension, and whilst most prevalent 
in the elderly, it may occur at any age (van Riet, et al., 2016).  
 
Patients with HF are grouped into phenotypic variants based on left ventricular ejection 
fraction (LVEF), a measure which is easily obtained via non-invasive transthoracic 
echocardiography that in HFrEF correlates strongly with HF mortality (Solomon, et al., 2005). 
Ejection fraction is not simply a measure of cardiac contractile function, but is influenced by 
ventricular size and by vasculoventricular (V-V) coupling (Borlaug & Kass, 2011). Just over 
half of patients with HF have an EF >50% and are said to have heart failure with preserved 
ejection fraction (HFpEF). Less than half of patients with HF have an EF <40% and are said to 
have heart failure with reduced ejection fraction (HFrEF). Interestingly, 10-20% of patients 
with HF have a mid-range LVEF (HFmEF) between 40 and 50%, some of whom have 
‘recovered’ function, and this syndrome is now becoming increasingly recognized as a 
separate entity to HFrEF and HFpEF, bearing similarities with the latter (Nadruz, et al., 
2016).  
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The HF syndrome may manifest clinically as dyspnea, fatigue, exercise intolerance, and 
peripheral oedema. HFpEF is characterized by raised left ventricular end diastolic pressure 
(LVEDP) due to diastolic dysfunction, however there is also evidence in many patients of 
systolic dysfunction (despite the normal LVEF). Furthermore, as in HFrEF, there is frequently 
chronotropic incompetence, impaired peripheral vascular function and neurohormonal 
activation (Bursi, et al., 2006; Kitzman, et al., 2002; Yancy, et al., 2006). HFrEF and HFpEF 
affect distinct patient groups, and therapies that have been shown to significantly improve 
mortality in HFrEF have failed to show similar benefits in HFpEF, despite many being 
targeted at maladaptive responses common to both (Kitzman, et al., 2010; Massie, et al., 
2008; Yusuf, et al., 2003). The guideline-directed therapies employed in HFrEF have been 
reviewed extensively (Lother & Hein, 2016; Loudon, et al., 2016), and are aimed at reducing 
neurohormonal activation (e.g. β-adrenergic receptor antagonists; angiotensin converting 
enzyme [ACE] inhibitors; angiotensin II receptor blockers [ARB]; mineralocorticoid receptor 
antagonists [MRA]; neprilysin inhibitor-ARB combination drugs) and correcting volume 
overload (diuretics) and altered haemodynamics (vasodilators and inotropic agents; 
Ponikowski, et al., 2016; Yancy, et al., 2013). There are currently no evidence-based 
therapies for HFpEF, and despite the range of therapies available in HFrEF, the prognosis 
remains poor (Owan, et al., 2006), thus demonstrating an urgent need for new therapies in 
both conditions.  
 
There has been increasing interest in the role of energetic impairment in the etiology, 
pathophysiology, and progression of HF (Hunter, et al., 2016; Neubauer, 2007; Pascual & 
Coleman, 2016), and in agents that may correct this, by altering cardiac substrate utilization; 
improving mitochondrial electron transport chain (ETC) function; or increasing energy 
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transfer from the mitochondrion to the cytosol (Siddiqi, et al., 2013). Agents have shown 
promise in HFrEF, include trimetazidine and perhexiline. Intravenous dichloroacetate (DCA) 
has been show to improve cardiac output via improved mechanical efficiency. Other 
metabolic agents are yet to be evaluated, whilst others are yet to show any benefit (Chong, 
et al., 2016). In this review, we will briefly outline the pathophysiology of HF, focusing on 
metabolic disturbances, and discuss the current evidence behind therapeutic agents used to 
correct metabolic dysfunction.  
 
2. The Pathophysiology of Heart Failure 
2.1 Heart Failure with Reduced Ejection Fraction 
HFrEF typically occurs as a result of an acute insult (e.g myocardial infarction), a chronic 
insult (e.g. hypertension, valvular heart disease), or may be a consequence of 
autoimmune/infective causes, genetic mutations, or infiltrations/depositions (e.g 
sarcoidosis, amyloidosis). A severe reduction in EF is representative of a reduction in 
contractile function, maladaptive ventricular remodeling, and dysfunctional 
vasculoventricular and interventricular coupling (Kass, et al., 1987; Ky, et al., 2013). This 
translates to an increase in LVEDP and left ventricular end diastolic volume (LVEDV). 
Recruitment of the intrinsic Frank-Starling mechanism due to increased LVEDV blunts the 
fall in stoke volume (SV) at rest in less severe cases, but there is an inability to increase SV 
on exercise, especially in the presence of coronary artery lesions (Lele, et al., 1996; 
Sumimoto, et al., 1997). In more severe cases SV may also be substantially reduced at rest. 
The force-frequency relation is also flat or even negative in HFrEF (Gwathmey, et al., 1987), 
which contributes to the fall in CO reserve. Deficient cardiovascular reserve culminates in 
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exercise intolerance and in more severe cases severe HF develops at rest resulting in 
hospitalization, which is often recurrent.  
 
End-organ hypoperfusion (e.g. renal hypoperfusion or ischemia of neurons in the 
hypothalamic paraventricular nucleus [PVN]; Sharma, et al., 2016) and baroreflex 
impairment activate neurohormonal compensatory mechanisms. These attempt to retain 
salt and water (increasing preload to recruit the Frank-Starling mechanism), cause 
vasoconstriction to maintain cerebral perfusion pressure, and increase cardiac inotropic, 
chronotropic, and lusitropic function. These mechanisms include sympathetic nervous 
system activation and inhibition of vagal activity (Jackson, et al., 2000), activation of the 
renin-angiotensin-aldosterone system (RAAS), and release of the osmoregulatory hormone 
vasopressin. Angiotensin II has also been shown to activate neurons in the PVN to further 
increase sympathetic tone (Chen, et al., 2011). Chronically however, elevated 
catecholamines are arrhythmogenic and toxic, due to cyclic adenosine monophosphate 
(cAMP)-mediated calcium overload which is pro-apoptotic (Mann, et al., 1992). Sensitivity of 
cardiac muscle to β-adrenergic stimulation is also reduced in HFrEF, with a reduction in β1-
receptor density (Bristow, et al., 1982) and desensitization of receptors (either directly via 
PKA or G protein–coupled receptor kinase dependent phosphorylation, or via eNOS-
coupling; Lohse, 1995) which, coupled with autonomic dysfunction, contributes to 
chronotropic incompetence, further worsening exercise intolerance.  
 
A raised LVEDV causes progressive LV cavity dilatation, which increases wall stress 
(afterload) according to Laplace’s law. Ventricular wall stress/stretch further activates the 
RAAS to compensate, and the local, tissue effects of chronic pro-hypertrophic angiotensin II 
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promotes remodeling by way of increased protein synthesis, interstitial fibrosis, and 
inflammation (Paul, et al., 2006). Pathological remodeling of the electrical system also 
occurs, often leading to left bundle branch block (LBBB) and ventricular dyssynchrony. These 
structural changes contribute to a reduction in left ventricular contractility as represented 
by end systolic elastance (Ees), the slope of the left ventricular end systolic pressure-volume 
relation (ESPVR). The gold-standard for the assessment of V-V coupling is via analysis of 
invasive pressure-volume recordings to create PV loops. If obtained during progressive IVC 
balloon-occlusion, one can plot the end systolic pressure (ESP) for each loop to create the 
linear ESPVR and calculate its slope, the Ees, a relatively load-independent measure of 
systolic function (Gillebert, et al., 1997). Ees may also be estimated from a non-invasive 
single beat method using echocardiography, which correlates well with invasive measures 
(Chen, et al., 2001). Arterial elastance (Ea), a grouped measure of both pulsatile and static 
components of afterload, may also be calculated as the negative slope of a line drawn from 
the ESP to the end diastolic volume (EDV) on the volume (x) axis, representing ESP/SV (Kelly, 
et al., 1992). The ratio of Ea/Ees reflects V-V coupling, which is maximized for mechanical 
efficiency between a range of 0.3 and 1.3 (De Tombe, et al., 1993). In HFrEF, the V-V 
coupling ratio may be raised outside of this range due to a fall in the Ees secondary to the 
inciting cardiac insult, and as a result these patients respond well to afterload reduction 
with vasodilators and diuretics, showing an improvement in SV with relatively small changes 
in systolic blood pressure (Schwartzenberg, et al., 2012). V-V coupling ratio (but not Ees 
alone) and left ventricular size each correlate strongly with prognosis in HFrEF (Ky, et al., 
2013).  
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2.2 Heart Failure with Preserved Ejection Fraction 
HFpEF tends to occur in women more so than men, and in older, hypertensive patients with 
a wide range of cardiovascular comorbidities including the metabolic syndrome, diabetes 
mellitus, obesity, and endothelial dysfunction (Borlaug & Paulus, 2011). The observed 
features of diastolic dysfunction and systemic hypertension were initially taken as evidence 
that HFpEF is primarily caused by static ‘afterload excess’ (Hart, et al., 2001). However, early 
stage HFpEF is instead considered a disorder of depleted cardiovascular reserve, with 
exercise testing required to confirm the diagnosis outside of acute decompensation 
(Borlaug, et al., 2010; Obokata, et al., 2016). Given the diversity of cardiovascular conditions 
associated with HFpEF and the identification of distinct phenotypes of the syndrome, it is 
generally accepted that HFpEF represents a range of diseases rather than a single distinct 
entity (Lindman, et al., 2014;  Shah, et al., 2016), which further complicates the testing of 
new potential therapies. Indeed, it has recently been suggested that treatment of HFpEF 
should be targeted at components of the disease (e.g. statins for systemic inflammation and 
caloric restriction for metabolic syndrome), which would individualize therapy based on 
HFpEF phenotype (Shah, et al., 2016). HFpEF contains many features that are common to 
HFrEF (i.e. common to all HF), due to the limited range of responses available to the 
cardiovascular system. These features of HFpEF include diastolic dysfunction, impairment of 
systolic function and reserve, abnormal V-V coupling, inflammation and endothelial 
dysfunction, chronotropic incompetence and altered β-adrenergic signaling, pulmonary 
hypertension, renal disease, and altered cardiac and skeletal muscle metabolism (Sharma & 
Kass, 2014).   
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Recently, Paulus and Tschope (2013) outlined a novel paradigm for the pathophysiology of 
HFpEF, which centers on cardiovascular comorbidities and systemic inflammation 
culminating in reduced myocardial nitric oxide (NO) and cyclic guanosine monophosphate 
(cGMP) bioavailability due to reactive oxygen species (ROS)-related scavenging of NO 
(Paulus & Tschope, 2013). Outside the myocardium, the effects of systemic inflammation in 
various tissues culminate in the pulmonary hypertension, muscle weakness, and sodium 
retention which contribute to HFpEF phenotypic diversity (Cowley, et al., 2015; Dhakal, et 
al., 2015). This paradigm identifies the subsequent reduction in protein kinase G (PKG) 
activity and uncontrolled inflammation as the basis for disease development and 
progression, leading to increased passive tension of cardiomyocytes second to 
hypophosphorylation of the massive cytoskeletal protein titin (Borbely, et al., 2009), 
uncontrolled hypertrophy, and interstitial collagen deposition (van Heerebeek, et al., 2006; 
van Heerebeek, et al., 2012; Westermann, et al., 2011). ROS-dependent oxidation of titin in 
HFpEF further compounds passive cardiomyocyte tension, despite an observed shift in titin 
isoform expression from predominance of the N2B isoform to the larger and more 
compliant N2BA isoform (Borbely, et al., 2005). In HFrEF, the inflammation occurs at the 
level of the cardiomyocyte, with the development of systemic inflammation being a late 
feature of the disease. This novel paradigm poses many important therapeutic questions, 
such as the potential for increased benefit from cardiovascular therapies with ancillary anti-
inflammatory properties, in terms of disease progression and prognosis. It also goes some 
way to explaining the recent positive results with inorganic nitrate and nitrite to supplement 
myocardial NO in HFpEF (Borlaug, et al., 2015; Borlaug, et al., 2016), and outlines a 
beneficial mechanism for the use of neprilysin inhibitor-ARB combination (ARNI) drugs in 
HFpEF beyond neurohormonal regulation, which has been otherwise unsuccessful in 
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treating this disease (Yusuf, et al., 2003). The increased levels of natriuretic peptides 
following ARNI treatment activate myocardial natriuretic peptide receptors, which are 
linked to particulate guanylate cyclases, thus restoring cGMP bioavailability (von Lueder, et 
al., 2013).  
 
As noted, LVEF is a grouped variable which represents a number of components such as 
contractile function, ventricular remodeling, and V-V coupling, and despite preservation of 
LVEF at rest, these components are usually all abnormal in HFpEF compared to healthy 
controls. Following improvements in imaging techniques, such as the development of strain-
gauge echocardiography, evidence of mechanical dyssynchrony and subtle defects in 
longitudinal and radial systolic function have been identified (Tan, et al., 2009).  Compared 
to HFrEF, the LV in HFpEF is typically hypertrophied with a normal LV cavity radius (and 
therefore lower wall stress), with lower serum natriuretic peptide levels and neurohormonal 
activation (Iwanaga, et al., 2006). However, the LV filling pressure, elevated due to reduced 
LV compliance, is therefore reflected back into the left atrium and pulmonary circulation in 
HFpEF, increasing the incidence of atrial fibrillation, pulmonary hypertension and right 
ventricular dysfunction (Guazzi & Borlaug, 2012). This increase in pulmonary capillary wedge 
pressure (PCWP) is markedly worsened on exercise. It is important to note that V-V coupling 
is also abnormal at rest in HFpEF, despite maintenance of the Ea/Ees ratio within the normal 
range (Borlaug, et al., 2009). The grouped measure of afterload stresses, Ea, is significantly 
elevated in these patients, due to calcific arterial stiffening (static component), and 
propagation of reflected waves from arterial impedance mismatch (pulsatile component) 
causing them to arrive in late systole rather than early diastole, further adding to LV 
afterload (Borlaug, et al., 2007; Kelly, et al., 1989). In response, the Ees (or ventricular 
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stiffness) must increase to maintain mechanical efficiency, resulting in a normal Ea/Ees 
ratio. As a result, patients with HFpEF have impaired reserve of V-V coupling, which is best 
demonstrated with invasive exercise testing. On exercise in health, the Ea increases slightly 
with a significantly greater increase in Ees, which causes the V-V coupling ratio to fall (and 
the inversely related LVEF to increase), increasing cardiac efficacy (Najjar, et al., 2004). On 
exercise in HFpEF, due to a loss of Ees reserve and a further increase in the already elevated 
Ea the ratio remains unchanged, reducing cardiac efficacy and increasing the energy cost of 
LV stroke work (Phan, et al., 2009). The increased slope of the ESPVR (Ees) also results in 
large changes in systolic blood pressure for a given change in LV end systolic volume 
(LVESV). As a result, patients with HFpEF are more ‘volume sensitive’ than those with HFrEF, 
with a narrow window observed between the extremes of pulmonary oedema and pre-renal 
failure with diuretic therapy (Gandhi, et al., 2001).  
 
Whether altered metabolic function is a cause of HF or an effect is not always obvious. 
Energetic dysfunction may contribute to the natural histories of both HFrEF and HFpEF 
regardless of etiology.  All HF (and indeed LV hypertrophy even in the absence of HF) has 
been shown to possess a component of altered cardiac and skeletal muscle metabolism, and 
the severity of this alteration correlates with disease progression (Neubauer, et al., 1992). 
Lower PCr/ATP ratios on phosphorous magnetic resonance spectroscopy (31P MRS) 
compared to healthy controls have been demonstrated in patients with LV hypertrophy, 
HFrEF, and HFpEF, manifest as a reduction in the ratio of resting cardiac PCr/ATP and in the 
case of skeletal muscle, a slowing of the rate of recovery of PCr following exercise 
(Neubauer, et al., 1992; Phan, et al., 2009). Several mechanisms contribute to this energetic 
impairment, including decreased efficiency of energy use, mechanical dyssynchrony, 
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microvascular disease, downregulation of key metabolic enzymes, and impaired 
mitochondrial ETC function (Stanley, et al., 2005).  
 
3. Cardiac Metabolism and Energetic Status in the Normal Heart and in Heart Failure 
Under normal physiological conditions, the myocardium relies upon a constant supply of 
ATP to fuel its continuous contractile function and ion channel activity (primarily for 
myocardial calcium [Ca2+] handling), cycling approximately 6 kg per day (Neubauer, 2007; 
see Fig 1). During the fasting state, approximately 70% of cardiac ATP production is achieved 
through free fatty acid (FA) metabolism, with approximately 20% being produced via 
carbohydrate metabolism and the remaining through the oxidation of ketones, lactate, and 
amino acids (Bing, et al., 1954; Lopaschuk, et al., 1994). There is a wealth of evidence 
showing significant shifts in cardiac metabolism and subsequent impairment of energetic 
status in HF; indeed, severe metabolic imbalance is recognized as an integral feature of the 
disease (Doenst, et al., 2013). Explanted failing human hearts, and rat hearts with coronary 
artery ligation induced-HF, have dramatically lower levels of PCr than healthy controls 
(Neubauer, et al., 1999). Smith and colleagues (2006) quantified a 35% decrease in cardiac 
PCr in patients with LV hypertrophy (Smith, et al., 2006). Other models of HF, such as a 
porcine model of pressure-overload-induced HF (Jameel, et al., 2016) and a canine model of 
tachycardia  induced HF (Xiong, et al., 2015), have shown similar results.   
 
PCr/ATP ratio, obtained via in vivo non-invasive 31P MRS, was found to be reduced in 
patients with HFrEF due to dilated cardiomyopathy (DCM) and the magnitude of this 
reduction correlated with New York Heart Association (NYHA) functional class and mortality 
(Neubauer, et al., 1997). Reduced PCr/ATP ratio has been reported in a wide range of 
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cardiomyopathies including hypertrophic cardiomyopathy (HCM), the commonest inherited 
cardiac condition worldwide, and these changes preceded hypertrophy in many cases (de 
Roos, et al., 1992). Our group has also demonstrated a significant reduction in cardiac 
PCr/ATP ratio in patients with HFpEF, and this reduced energetic reserve is likely responsible 
for the dynamic slowing of LV active relaxation and inability to improve (reduce) V-V 
coupling ratio during exercise observed in these patients (Phan, et al., 2009). The use of 
dynamic (exercise) 31P MRS allows for quantification of PCr recovery kinetics in skeletal 
muscle, such as PCr recovery rate, which is prolonged in HF (Chance, et al., 2006). Post-
exercise PCr recovery rate (kPCr) represents the replenishment of the cytosolic PCr pool from 
ATP produced at the ETC, which is a marker of mitochondrial oxidative capacity.  
 
Recently, Cunningham and colleagues demonstrated the feasibility of hyperpolarized-
carbon metabolic magnetic resonance spectroscopy (13C MRS) in man, following a 0.1 
mmol.kg-1 dose of hyperpolarized [1-13C]pyruvate in 4 healthy subjects (Cunningham, et al., 
2016). 13C MRS of the heart has the distinct advantage over 31P MRS of providing real-time 
data relating to the in vivo metabolism of pyruvate, upstream of the ETC. This technique 
allows for appreciation of the various fates of pyruvate through anaerobic glycolysis or 
mitochondrial oxidation, by measuring 13C-tagged metabolites (e.g. bicarbonate, lactate, 
and alanine) immediately following intravenous administration (Merritt, et al., 2007). This 
represents an exciting new avenue for expanding our understanding of cardiac metabolism 
and energetic status, and for testing novel therapies.  
 
There are several mechanisms that contribute to the energetic impairment observed in HF. 
These may include microvascular dysfunction or ischemia, energy-wasting mechanisms, 
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impairment of energy transfer to the point of utilization within the cytosol, increased 
oxidative stress, and defective energy extraction from available substrates. 
Ischemia/hypoxia in the failing ventricle (with poor reserve) is worsened by tachycardia 
(such as with exercise or with AF, which has a high prevalence in HF), with a reduction in 
diastolic filling where the majority of coronary flow occurs. In HF, myocardial oxygen supply 
may be further affected by the previously mentioned shift of reflected aortic waves to late 
systole rather than early diastole (due to increased pulse wave velocity in the stiff aorta), 
augmenting systolic blood pressure (afterload) and reducing myocardial perfusion pressure 
during diastole (Borlaug, et al., 2007).  
 
Hypertrophic growth may also be considered an energy ‘sink’, requiring the rerouting of 
glycolytic intermediates and other metabolic by-products to support substantial protein 
synthesis. Other mechanisms that may ‘waste’ energy include intra-ventricular 
dyssynchrony (demonstrated by altered strain gauge imaging; Phan, et al., 2009), inter-
ventricular dyssynchrony e.g diastolic ventricular interaction (Atherton, et al., 1997), and 
detoxification of ROS and nitrosative stress. Energy transfer from the mitochondria to the 
sites of utilization within the cytosol is also impaired in HF due to changes in the CK system 
(Ingwall, 1984), including reduced sodium (Na+)-creatine cotransporter protein content 
(Neubauer, et al., 1999) and impaired cytosolic CK activity due to oxidative stress (Ventura-
Clapier, et al., 2011). Perhaps the most complex mechanism, and one which offers 
numerous potential pharmacological targets for metabolic modulation in HF, is that of 
altered substrate metabolism (Fig 2). Metabolism in advanced HF is thought to revert back 
to the fetal metabolic profile, with a decrease in FA metabolism despite preserved cytosolic 
FA uptake, and a shift towards glucose uptake and glycolysis (Fillmore & Lopaschuk, 2013; 
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Pascual & Coleman, 2016). However, there is evidence to show that terminal oxidation of 
both FA and glucose by the mitochondria is downregulated in HF, with compensatory 
funneling of pyruvate into anaplerotic pathways and increased ketone metabolism (Aubert, 
et al., 2016).  
 
3.1 Fatty acid metabolism  
Free FA enters the myocardium from the bloodstream either passively or through facilitated 
uptake by FA transporters (mainly CD36) and plasma membrane FA binding proteins. Within 
the cardiomyocytes, the short and long chain FAs are esterified into short chain fatty acyl 
coenzyme A (CoA) or long chain fatty acyl-CoA, respectively. The short chain fatty acyl CoA 
diffuses through the inner mitochondrial membrane into the mitochondria, however long 
chain fatty acyl CoA must first enter the ‘carnitine shuttle’ (van der Vusse, et al., 2000). The 
carnitine shuttle involves the addition of carnitine to long chain acyl CoA esters by the 
enzyme carnitine palmitoyltransferase 1 (CPT1) to generate long chain acyl carnitine, which 
is able to cross the outer mitochondrial membrane. CPT1 is thus the rate-limiting enzyme in 
long chain fatty acid metabolism. At the inner mitochondrial membrane, the enzyme CPT2 
cleaves the carnitine off, which is then re-exported across the mitochondrial membrane.  
 
Entry of long chain fatty acyl CoA into the mitochondria via CPT1 is regulated by excess 
tricarboxylic acid (TCA) cycle intermediates in times of energy excess, and by AMP-activated 
protein kinase (AMPK) in times of low cellular energy content. Excess citrate from the TCA 
cycle is transported into the cytosol where it is converted to acetyl CoA and oxaloacetate by 
ATP citrate lyase (Hue & Taegtmeyer, 2009). Cytosolic acetyl CoA is further converted to 
malonyl CoA by the enzyme acetyl CoA carboxylase (ACC), which may be converted back 
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into acetyl CoA by malonyl CoA decarboxylase (MCD). Malonyl CoA is a naturally occurring 
inhibitor of CPT1, thus carefully regulating the entry of free FAs into the mitochondria, as 
excess FA may react with mitochondrial ROS to produce lipid peroxides which damage 
mitochondrial DNA (Schrauwen, et al., 2001). AMPK activation by AMP in low energy states 
inhibits ACC and reduces malonyl CoA levels (thereby relieving inhibition of CPT1) and 
increases FA entry into the mitochondria to be oxidized by the β-oxidation machinery. AMPK 
also recruits CD36 to the sarcolemma, increasing cellular FA uptake (Samovski, et al., 2015).  
 
Once inside the mitochondria, the long chain acyl CoA molecule undergoes a number of 
oxidation steps known as β-oxidation, ultimately generating acetyl CoA, nicotinamide 
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2). Acetyl CoA then 
enters the TCA cycle. β-oxidation enzymes are regulated by the peroxisome proliferator 
activated receptor (PPAR) family of transcription factors, PPARα and β/δ (Gilde, et al., 2003). 
PPARα also upregulates pyruvate dehydrogenase kinase (PDK) 4 in the myocardium which 
inhibits pyruvate dehydrogenase (PDH) activity, the rate-limiting enzyme for pyruvate 
metabolism, an example of FA-glucose co-regulation (Wu, et al., 2001). A further member of 
the PPAR family, PPARγ, which is expressed in the intestine and at high levels in adipose 
tissue, may also be activated within cardiomyocytes. In the heart, PPARγ activation 
increases free FA and glucose uptake, and glycerolipid biosynthesis (Krishnan, et al., 2009). 
PPARs are regulated by free FA and the transcriptional co-factor, PPARγ cofactor 1α 
(PGC1α), which is a master regulator of mitochondrial biogenesis (Handschin & Spiegelman, 
2008). PGC1α is potently activated by cold and is therefore linked to the ‘browning’ of 
adipose tissue (by activating PPARγ, which upregulates mitochondrial uncoupling protein 1 
(UCP1) expression in adipocytes; Puigserver, et al., 1998). The activities of PGC1α and AMPK 
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are further regulated by the sirtuins (SIRT), a group of histone deacetylases which serve as 
‘anti-aging’ enzymes and metabolic sensors that are activated by high NAD+/NADH ratios in 
states of energy depletion (Nemoto, et al., 2004; Oka, et al., 2015). SIRT-3 has been shown 
to phosphorylate and activate AMPK (Palacios, et al., 2009), and SIRT-1 has been shown to 
activate PGC1α via deacetylation (Rodgers, et al., 2005).  
 
In HF, there is reduced activity of the PPAR transcription-factor pathways, which results in 
downregulation of enzymes from the β-oxidation spiral (Pellieux, et al., 2006). A limitation in 
cardiac O2 supply may also limit FA oxidation, due to the relatively high cost of FA oxidation 
compared to glucose oxidation (Jaswal, et al., 2011). Furthermore, mitochondrial ROS and 
uncoupling of oxidative phosphorylation in HF lead to reduced production of ATP from FA 
oxidation (Tsutsui, et al., 2011). The energetic deficit also activates AMPK, which increases 
sarcolemmal expression of CD36, increasing FA entry into the cytosol. Coupled with lipolysis, 
and the subsequent liberation of FA from adipose tissue secondary to systemic 
neurohormonal activation, there is a resultant over-supply of free FA in the cardiomyocyte, 
which is prevented from entering terminal oxidation. Downregulation of the β-oxidation 
pathway was first identified in 1996 by Sack and colleagues in a study of left ventricular 
biopsies of patients with terminal HF and in rats with progressive LV hypertrophy, which 
demonstrated a >40% decrease and >70% decrease in the expression of β-oxidation 
enzymes, respectively (Sack, et al., 1996). A study by Neglia et al. (2007) also reported that 
in DCM patients with symptoms of HF, FA uptake and oxidation were reduced compared to 
the control group. Barger and colleagues observed a decrease in PPARα gene expression 
and activity in hypertrophic rat cardiomyocytes and hearts from mice subjected to 
transverse aortic constriction (TAC; Barger, et al., 2000). PPARα expression was also reduced 
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in mice with HF induced by chronic angiotensin II stimulation, with a reduction in mRNA 
expression of enzymes involved in FA metabolism such as CPT1 (Pellieux, et al., 2006). 
PPARα has been shown to be downregulated in failing human hearts (Karbowska, et al., 
2003). PGC1β knock-out mice subjected to TAC experienced a rapid progression towards HF, 
extreme mitochondrial dysfunction, markedly reduced cardiac efficiency, and elevated 
levels of oxidative stress when compared to wild-type litter mates also subjected to TAC 
(Riehle, et al., 2011). Identical results have been found in PGC1α deficient TAC-mice (Arany, 
et al., 2006; Lu, et al., 2010). However, Lionetti et al. found in a pacing-induced canine 
model of HF that PPARα and PGC1 protein levels did not significantly differ from the control 
hearts (Lionetti, et al., 2005). SIRT-1 is also down-regulated in HF (Fukushima & Lopaschuk, 
2016). In spontaneously hypertensive rats, compensatory cardiac hypertrophy was 
accompanied by a decrease in SIRT-1 expression (Tang, et al., 2014). Similarly, SIRT-1 
expression was reduced in patients with both compensated and decompensated HF (Akkafa, 
et al., 2015) and in patients with advanced HF (Lu, et al., 2014). In both of these studies, 
SIRT-1 downregulation was associated with an increase in oxidative stress and pro-apoptotic 
signaling. A decrease in SIRT-3 levels in hypertrophied TAC mouse hearts (Chen, et al., 2015) 
and SIRT-6 expression in human failing hearts (Sundaresan, et al., 2012) have also been 
reported; SIRT-6 deficient mice also developed hypertrophy and cardiac failure.  
 
Recently, Shibayama and colleagues (2015) identified significant reductions in carnitine and 
FA levels in the mitochondria of canine hearts with pacing-induced HF (Shibayama, et al., 
2015). Moreover, it has also been found that the expression and/or activity of other 
enzymes required for mitochondrial FA uptake and oxidation, such as muscle CPT1 and acyl-
CoA synthetase are downregulated compared to controls (de Brouwer, et al., 2006; Lionetti, 
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et al., 2005; Pellieux, et al., 2006). A reduction in FA uptake and oxidation was observed in 
HF induced by a high-salt diet in rats (Kato, et al., 2010) and in canines with tachycardia 
induced HF (Osorio, et al., 2002). In addition, FA oxidation rates and enzyme expression 
were reduced in rats subjected to abdominal aortic constriction to induce HF (Akki, et al., 
2008). A reduction in myocardial carnitine has also been previously reported in patients with 
HCM and signs of chronic HF (Regitz, et al., 1990) as well as a decrease in FA oxidation in 
symptomatic DCM patients (Neglia, et al., 2007; Yazaki, et al., 1999). Interestingly, previous 
reports by Paolisso and colleagues demonstrated findings to the contrary, with HF patients 
having a ~40% increase in FA uptake and oxidation despite no change in coronary blood flow 
(Paolisso, et al., 1994). It has therefore been suggested that the way in which HF is induced 
and HF severity in these studies may dictate the changes observed in metabolism (Doenst, 
et al., 2013), and this is also true for the alterations in carbohydrate metabolism.  
 
It has been reported that triacylglycerol (TAG) pool dynamics are also dysregulated in the 
failing heart, with an associated rise in diacylglyceride (DAG) and ceramide, which have been 
implicated in lipotoxicity (Carley & Lewandowski, 2016). The falling levels of long chain free 
FA from this altered TAG turnover lead to reduced signaling via the PPARα pathway (as long 
chain free FA is an important ligand for PPARα activation; Lahey, et al., 2014). O’Donnell et 
al. (2008) observed a significant reduction in TAG content and turnover in rats subjected to 
pressure-overload HF, due to an upregulation in the TAG hydrolase, and adipose triglyceride 
lipase enzyme (O'Donnell, et al., 2008). A reduction in TAG content and increased levels of 
toxic lipid intermediates were also found in patients with chronic HF, and this was 
successfully corrected following mechanical unloading with left ventricular assist device 
(LVAD) therapy (Chokshi, et al., 2012). Levels of toxic lipid intermediates have also been 
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shown to be increased in rats subjected to TAC (Lahey, et al., 2014). The same group also 
identified that TAG turnover rate is also of critical importance in HF, rather than simply 
content, and normalizing TAG turnover rate via supplementation with the dietary FA oleate 
led to improved FA metabolism and contractile function in TAC rats (Lahey, et al., 2014). 
Thus, restoration of TAG dynamics, e.g. through supplementation of natural and dietary 
long-chain FAs, provide an additional therapeutic strategy in HF that warrants further 
investigation.  
 
3.2 Glucose metabolism 
Glucose enters the cardiomyocyte via the glucose transporters (GLUT1 and GLUT4). 
Following uptake, glucose is converted to glucose-6-phosphate (G6P) by hexokinase on the 
inner surface of the cell membrane, and this G6P enters the glycolytic pathway to generate 
pyruvate. G6P may also enter the pentose phosphate pathway (PPP) to produce NAD(P)H, 
which is essential for detoxifying cellular ROS (Ussher, et al., 2012). In addition, enzymes and 
products of the glycolytic pathway play an important role in cellular anabolism, as they may 
enter biosynthetic pathways such as the hexosamine biosynthetic pathway (HBP) to 
increase cellular biomass (Doenst, et al., 2013). Pyruvate from glycolysis is transported 
across the mitochondrial membrane by pyruvate translocase (an active, energy requiring 
process). Mitochondrial pyruvate is decarboxylated by the rate-limiting PDH complex, to 
form acetyl CoA, the common end-product of glucose oxidation and FA β-oxidation. PDH 
activity is regulated positively by PDH phosphatases and negatively by PDH kinases 
(Kolobova, et al., 2001), and is inhibited by its by-products acetyl CoA and NADH (Stanley, et 
al., 2005). A fall in mitochondrial ATP production such as in hypoxia or with mitochondrial 
dysfunction causes a fall in the cytosolic ATP/ADP ratio, which activates glycolysis 
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(Maldonado & Lemasters, 2014). In addition during hypoxia, breakdown of the ubiquitous 
hypoxia inducible factor 1α (HIF1α) by oxygen-dependent cytosolic prolyl hydroxylase is 
inhibited, resulting in HIF1α accumulation and translocation to the nucleus (Lei, et al., 2008). 
HIF1α upregulates the expression of PDK 1, inhibiting glucose oxidation, as well as GLUT4 
and many enzymes involved in glycolysis, thus upregulating the precursors of the HBP and 
PPP (to detoxify hypoxia-generated ROS) and diverting pyruvate towards compensatory 
anaerobic glycolysis (to maintain ATP production), or anaplerosis. Chronic HIF1α 
accumulation in hypertrophied hearts has also been shown to activate PPARγ in 
cardiomyocytes, thus promoting glycerolipid formation via the glycerol-3-phosphate 
pathway, which causes TAG accumulation, apoptosis, and contractile dysfunction (Krishnan, 
et al., 2009). 
 
Insulin resistance frequently occurs in HF (Ashrafian, Frenneaux et al., 2007) and reduces 
insulin-stimulated glucose uptake. However, uptake through insulin-independent GLUT- 
signaling may compensate (e.g. via AMPK signaling or GLUT1 upregulation), and most 
studies suggest that glucose uptake and glycolysis are maintained or increased in HF 
(Tenenbaum & Fisman, 2004). However, in a rat TAC model of HF, despite increased 
glycolysis, there was no parallel increase in flux through the PDH enzyme complex, which led 
to the uncoupling of glycolysis from glucose oxidation (Sorokina, et al., 2007). Furthermore, 
the fall in glucose oxidation was accompanied by a compensatory increase in anaplerosis, to 
replace TCA intermediates which undergo terminal oxidation or are used for biosynthetic 
pathways as a result of hypertrophic remodeling in the failing heart. In combination, these 
mechanisms contribute to impaired energy generation from carbohydrate metabolism, 
despite the ready availability of glucose. Such findings have also been confirmed in a mouse 
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TAC model (Dai, et al., 2012), and it has been suggested that this detrimental uncoupling of 
glycolysis and glucose oxidation can be exacerbated by reduced FA oxidation, due to the 
Randle cycle which further upregulates glycolysis (Fillmore & Lopaschuk, 2013). Elevated 
levels of HIF1α, which occurs secondary to tissue hypoxia as discussed above, also 
contribute to the upregulation of glycolysis in HF (Holscher, et al., 2012).   
 
In another mouse TAC study, cardiac glucose oxidation was found to be decreased by 66% 
(Zhabyeyev, et al., 2013), with a further study demonstrating a reduction in PDH activity and 
gene expression in HF, which may explain these findings (Lei, et al., 2004). Kato and 
colleagues induced chronic HF in Dahl salt-sensitive rats by implementing a high salt diet 
and observed a downregulation in gene expression of PDH, as well as other proteins 
involved in glycolysis such as GLUT4, phosphofructokinase and phosphoglucomutase (Kato, 
et al., 2010). In rats with pressure overload induced HF, a progressive decline in glucose 
oxidation was observed (Doenst, et al., 2010). However, not all HF models demonstrate this. 
Osorio et al reported an increase in glucose oxidation rates in a canine model of rapid 
pacing-induced HF (Osorio, et al., 2002). Cellular glucose oxidation rates and β oxidation 
rates are closely interrelated and closely regulate each other via the aforementioned 
‘Randle cycle’. The Randle cycle (Randle, et al., 1963) is the phenomenon whereby increased 
acetyl CoA from FA β-oxidation directly inhibits the PDH complex, as well as being 
transported to the cytosol and converted to citrate, which subsequently inhibits the rate-
limiting glycolytic enzyme, phosphofructokinase. Conversely, when carbohydrate 
metabolism is increased, citrate from the tricarboxylic acid (TCA) cycle is transported to the 
cytoplasm where it is converted to acetyl CoA, and then into malonyl CoA which blocks 
CPT1, in turn decreasing FA metabolism.  
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3.3 Ketone metabolism 
Ketones are the most energy-efficient fuel available in the body, and are produced in the 
liver from excess acetyl-CoA produced from β-oxidation of FA. Ketone levels in health are 
therefore regulated by lipolysis (liberation of FA from TAG stores), amount of free FA 
reaching the hepatocyte, transport across the mitochondrial membrane (via diffusion or 
CPT1), and FA β-oxidation (Lopaschuk, et al., 2010). In the heart, as in all extrahepatic 
tissues, ketone bodies (acetoacetate, β-hydroxybutyrate, and acetone) undergo terminal 
oxidation following conversion back into acetyl CoA (in a series of reactions catalyzed by β-
hydroxybutyrate dehydrogenase 1 [BHD1], succinyl CoA:3-oxoacid CoA transferase [SCOT], 
and mitochondrial acetyl-CoA acetyltransferase 1 [ACAT1]), or they may be redirected into 
lipogenic pathways, such as de novo lipogenesis via the enzymes ACC or fatty acid synthase 
(FAS), or the mevalonate pathway for cholesterol synthesis (Cotter, et al., 2013).  
 
It has been recently identified that ketone metabolism is altered both in animal models of 
HF and in patients with HF. Aubert and colleagues reported an upregulation in the ketone 
oxidative enzyme BHD1 in TAC HF mice (Aubert, et al., 2016). These changes occurred in 
parallel to the downregulation of proteins involved in FA utilization, thus suggesting that the 
failing heart switches to ketone bodies as an alternative fuel source. Bedi and co-workers 
also observed significant increases in substrates involved in ketone metabolism in non-
diabetic patients with advanced HFrEF (Bedi, et al., 2016). Ketongenic β-hydroxybutyryl-CoA 
levels, and β-hydroxybutyrate myocardial use, were markedly increased alongside decreases 
in myocardial lipid intermediates. The increase in ketone oxidation may have added effects 
on glucose and FA oxidation, as this could reduce the mitochondrial NAD+/NADH ratio and 
further inhibit β-oxidation enzymes such as long-chain 3-ketoacyl-CoA thiolase (LC 3-KAT; 
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Jaswal, et al., 2011). These findings have garnered much attention in the HF metabolic field 
and have highlighted the need for further investigation into the role of altered ketone 
metabolism in order to determine whether the observed changes are beneficial and 
contribute to increased glucose oxidation, or are detrimental to cardiac function (Bedi, et 
al., 2016; Kolwicz, et al., 2016).   
 
3.4 The TCA cycle and oxidative phosphorylation 
Acetyl CoA from FA, glucose, ketone and amino acid metabolism enters the TCA cycle and 
generates NADH and FADH2 (Schwarz, et al., 2014). These donate high energy electrons 
which are transferred between electron acceptors (iron-sulfur subunits, quinone species, 
and flavin mononucleotide) within 4 enzyme complexes, I to IV, located within the 
mitochondrial inner membrane. This electron transfer powers extrusion of protons across 
the inner mitochondrial membrane, termed the electron transport chain (ETC). This 
subsequently activates ATP synthase, located on the inner mitochondrial membrane, which 
produces ATP through phosphorylation of adenosine diphosphate (ADP). There is 
concurrent oxidation of hydrogen ions to form water, and thus oxidation is coupled to 
phosphorylation. Oxidative phosphorylation is responsible for the production of over 95% of 
ATP in the myocardium (Beer, et al., 2002). 
 
Due to the potential for premature electron leakage and subsequent binding with oxygen, 
the ETC is a site for the formation of ROS, which must be closely regulated in health to 
prevent overwhelming oxidative stress. Mitochondrial complexes I and III are well 
established as sites of superoxide production due to post-translational modification 
(Holmstrom & Finkel, 2014), and hyperphosphorylation of complex IV may also contribute 
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to increased ROS generation (Prabu, et al., 2006). At physiological levels, cellular ROS are 
signaling molecules in their own right via oxidation of key cellular proteins including 
enzymes (particularly those containing thiol moieties), either increasing or decreasing their 
activity (Hurd, et al., 2007). Furthermore, ROS produced at mitochondrial complex III at the 
onset of hypoxia inhibits prolyl hydroxylase, and is the primary mechanism for accumulation 
of the HIF1α protein (Chandel, et al., 2000). At elevated levels, superoxide reacts with NO to 
form peroxynitrite. Peroxynitrite reduces tetrahydrobiopterin (BH4) to BH2, which promotes 
uncoupling of endothelial nitric oxide synthase (eNOS; Milstien & Katusic, 1999). Uncoupled 
eNOS becomes a source of further ROS production, rather than ROS-scavenging NO. 
Peroxynitrite and other ROS also directly damage mitochondrial DNA, which activates the 
nuclear enzyme poly ADP-ribose polymerase 1 (PARP-1; Pacher & Szabo, 2007). NAD+ is a 
key substrate of PARP-1, which is subsequently depleted, causing impairment of ATP 
production at the ETC and from glycolysis, leading to metabolic dysfunction, inflammation 
and cell death. Counter-regulatory mechanisms of mitochondrial ROS include uncoupling 
proteins (e.g. UCP2 and 3 in cardiomyocytes) and adenine nucleotide translocase (ANT), 
which balance charges at the mitochondrial intermembrane space to dissipate the 
electrochemical gradient, and mitochondrial superoxide dismutase (SOD) and NAD(P)H 
which detoxify ROS (Azzu & Brand, 2010; Circu & Aw, 2010). The coordinated action of the 
respiratory chain complexes is dependent on their organization into functional units called 
respirasomes by the membrane phospholipid, cardiolipin (Szeto, 2014). Dissociation of the 
respirasomes leads to increased ROS generation and reduced ATP production (Lee & Tian, 
2015; Rosca & Hoppel, 2013).  
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HF culminates in impaired oxidative phosphorylation and ATP generation, both due to 
impaired substrate utilization and direct structural and functional changes in the 
mitochondria (Fillmore & Lopaschuk, 2013). In a rat TAC model of HFrEF, Bugger and 
colleagues identified detrimental changes in mitochondrial morphology and volume density, 
accompanied by a 53% decrease in expression of ETC proteins (Bugger, et al., 2010). In 
addition, the activity of the ETC complexes was found to be reduced in a canine rapid-pacing 
model of HF (Ide, et al., 1999) and in LV biopsies from patients with HF (Scheubel, et al., 
2002). In some models of HF, organization of the ETC complexes into respirasomes appears 
to be impaired which may play an important role in electron slippage with ROS generation. 
This may be due to reduced expression of cardiolipin or altered interaction between 
cardiolipin and the respiratory complexes (Rosca & Hoppel, 2013; Szeto, 2014). Increased 
ROS and oxidative stress increase compensatory UCP expression. Unfortunately, increased 
UCP expression also leads to an increase in heat generation with ATP generation, thereby 
rendering oxidative phosphorylation less efficient (Murray, et al., 2004). Murray and 
colleagues (2004) also identified that the elevated UCP levels were associated with 
increased circulating free FA levels in rats with chronically failing and infarcted hearts. UCP3 
has also been shown to interact with other redox regulating proteins such as thioredoxin 2 
(Trx2; Hirasaka, et al., 2011). It has been shown that Trx2 levels are reduced in the hearts of 
patients with DCM, and that Trx2 knock-out mice have a progressive decline in LV function 
leading to death by HF (Huang, et al., 2015). These effects may be related to the 
upregulation of TXNIP, which inhibits Trx2 (Chong, et al., 2014). In a mouse pressure-
overload model of HF, TXNIP knock-out mice initially had reduced cardiac hypertrophy and 
preserved LV contractile reserve compared to their wild-type litter mates (Yoshioka, et al., 
2012).  
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As discussed, increased ROS in HF leads to compensatory activation of PARP-1 (Pacher & 
Szabo, 2007). In a coronary artery ligation model of HF in rats, PARP-1 activation was 
increased alongside the reduction in LV function (Pacher, et al., 2002). Increased PARP-1 
activity is maladaptive in the setting of HF, as it leads to a reduction in the NAD+/NADH ratio 
by reducing the NAD+ pool, which reduces ATP production from pathways that require NAD+ 
as a substrate (Pillai, et al., 2005). PARP-1 inhibition with an experiment inhibitor L-2286 has 
since been shown to prevent cardiac remodeling, LV systolic dysfunction, and delay 
progression to HF, in rats with spontaneous hypertension (Bartha, et al., 2009). The 
deleterious changes in mitochondrial structure and function in HF are also due to the 
observed shifts in cardiac metabolism themselves. The reduced level of FA oxidation causes 
FA build up within the mitochondria, with lipid peroxide formation, whilst the decrease in 
glucose oxidation results in a build-up of lactate and hydrogen ions within the cell which 
alters cellular pH (Fillmore & Lopaschuk, 2013; Munzel, et al., 2015). The resulting oxidative 
stress and disturbances in cellular pH directly damage both the mitochondrial membrane 
and important mitochondrial proteins (Dai, et al., 2012). As such, targeting the metabolic 
changes of HF may also prevent the downstream perturbations of mitochondrial biogenesis, 
function and energy transfer, as well as improving ATP generation.  
 
4. Metabolic Modulators: Promising Therapeutic Agents 
Over the last decade, metabolic modulation for the treatment and management of HF has 
garnered increasing attention, primarily due to the rather slow-paced development of other 
novel pharmacotherapeutic agents. The debate as to whether the decrease in FA oxidation 
during HF is protective or maladaptive has also been central to the development and use of 
metabolic modulators. It is more or less believed that inhibiting FA metabolism in parallel to 
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enhancing glucose metabolism may be more beneficial (Doehner, et al., 2014). Such 
conclusions draw from evidence demonstrating that FA use is associated with an increase in 
ROS, which contributes to cardiac damage (Schonfeld & Wojtczak, 2007). Furthermore, in 
the presence of low oxygen levels, FA metabolism is a less efficient method for ATP 
production. Taking these considerations into account, many metabolic therapies focus on 
inhibiting FA metabolism and increasing glucose metabolism.  
 
Discussed below are several categories of metabolic modulating therapies, including 1) CPT1 
inhibitors, 2) partial FA oxidation inhibitors, 3) malonyl-CoA decarboxylase inhibitors, 4) 
increased FA utilization, 5) increased glucose utilization, 6) AMPK activators, and 7) 
mitochondrial-targeted antioxidants. The CPT1 inhibitor perhexiline and partial FA inhibitors 
trimetazidine and ranolazine, are also indicated for clinical use in the treatment of 
refractory angina. Table 1 also provides a summary of metabolic modulators that are 
currently under investigation in clinical trials, withdrawn from clinical use, or for which there 
is pre-clinical data only.  
 
4.1 Carnitine palmitoyltransferase 1 (CPT1) inhibition 
CPT1 is an essential enzyme in FA metabolism, being necessary for the uptake of long chain 
FA’s into the mitochondria. CPT1 inhibition, perhaps one of the most well-established and 
investigated forms of metabolic modulation, reduces long chain FA uptake and reciprocally 
increases carbohydrate oxidation via activation of PDH (Chong, et al., 2016). However, a 
recent metabolomics and proteomics study by Yin and colleagues, showed that perhexiline 
also donates protons within mitochondria to alter the redox environment, and increases 
lactate and amino acid uptake, which rebalances flux through the TCA cycle and increases 
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NADH concentrations improving cellular energetics (Yin, Dwyer et al., 2013). By reducing 
mitochondrial FA levels it also potentially reduces mitochondrial toxicity due to lipid 
peroxides. Several agents exist which inhibit CPT1, including: etomoxir, oxfenicine, 
perhexiline and ranolazine (Revenco & Morgan, 2009). Amiodarone (and the closely-related 
Dronedarone), a commonly used anti-arrhythmic drug, also possesses CPT1 inhibitor-
properties (Kennedy, et al., 1996). Although less potent than perhexiline, given the high use 
of this drug in clinical practice for prophylaxis against malignant ventricular 
tachyarrhythmias (common following AMI) and AF, these ancillary effects may be important 
in both the beneficial effects and side effects of this class (Kennedy, et al., 1996). CPT1 
inhibitors exert minimal haemodynamic effects, a clear benefit in comparison to many 
commonly used anti-anginals, avoiding symptomatic hypotension. In a small trial of patients 
with severe congestive HF, amiodarone therapy increased LVEF (19 ± 7% to 29 ± 15%; 
P<0.01), increased exercise tolerance and reduced the presence of non-sustained 
ventricular tachycardia (P=0.06; Hamer, et al., 1989).  These effects may be linked to CPT1 
inhibition, but could also be due to restoration of sinus rhythm from AF. The efficacy of 
amiodarone treatment in reducing ventricular arrhythmias in HF patients has been 
established in multiple large-scale clinical trials (Neri, et al., 1987; Nicklas, et al., 1991). 
 
A side effect of this class of drugs however, is the potential for phospholipidosis in various 
tissues (Ashrafian, Horowitz, et al., 2007). Liver lipidosis causing hepatotoxicity (Le Gall, et 
al., 1980) and neural lipidosis (in Schwann cells) causing neurotoxicity (Meier, et al., 1986) 
have been identified following perhexiline treatment, whilst systemic (Mazue, et al., 1984) 
and ocular lipidosis (Bockhardt, et al., 1978) have been observed with amiodarone. There is 
also the potential for hypoglycemia, which is a class-wide effect, due to the increase in 
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plasma glucose uptake. Moreover, in a retrospective analysis of the COMET trial, treatment 
with amiodarone in HF patients was associated with an increased risk of death from 
circulatory failure, independent of NYHA functional class, which may be due to the 
development of AV block in patients with a LVEF <30% (Torp-Pedersen, et al., 2007). Similar 
concerns have arisen for the use of dronedarone in HF, as there was an increase in mortality 
in patients with severe HF in the treatment arm compared to the placebo group (Kober, et 
al., 2008).  
 
Etomoxir is an irreversible inhibitor of CPT1 (Horowitz, et al., 2010). In a rat ascending aortic 
constriction model of HF, etomoxir treatment for 12 weeks increased LV maximal developed 
pressure and contractile performance, and reduced LV wall stress (Turcani & Rupp, 1997). 
Another study by Turcani and Rupp showed, using the same rat pressure overload HF 
model, that etomoxir treatment for 6 weeks enhanced LV function and prevented dilatation 
of the left ventricle (Turcani & Rupp, 1999). A first-in-human study in 10 HF patients 
confirmed these beneficial effects in the myocardium (Schmidt-Schweda & Holubarsch, 
2000). Treated patients showed an increase in EF (21.5 ± 2.6% to 27.0 ± 2.3%; P<0.01) and 
CO following exercise (from 9.7 ± 1.3 L.min-1 to 13.4 ± 1.5 L.min-1; P<0.01). Unfortunately, 
clinical investigations into etomoxir therapy have largely ceased. This is due to the outcome 
of a trial of 260 patients with moderate HF, in which etomoxir therapy led to the 
development of abnormally high levels of liver transaminases in some patients and 
established hepatotoxicity in others (Holubarsch, et al., 2007). Therefore, investigations into 
the safety of this drug are necessary before commencing new clinical trials. 
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Oxfenicine is an effective irreversible CPT1 inhibitor that was originally developed for use in 
patients with chronic stable angina (Revenco & Morgan, 2009). In a canine coronary artery 
occlusion HF model, oxfenicine therapy reduced FA accumulation with a concomitant 
reduction in infarct size (72 ± 2% vs 96 ± 3%; P<0.05; Vik-Mo, et al., 1986). A study by 
Kennedy and colleagues also revealed that oxfenicine attenuated the rise in LVEDP following 
low-flow ischemia in a rat HF model (Kennedy, et al., 2000). Both of these studies highlight 
the beneficial effects of oxfenicine-induced FA oxidation inhibition within the myocardium 
under ischemic conditions. Lionetti and colleagues (2005) also demonstrated, in a canine 
pacing-induced HF model, that oxfenicine treatment reduced LV dilatation and 
hemodynamic alternations (Lionetti, et al., 2005). Furthermore, oxfenicine prevented the 
significant LV wall thinning observed in the placebo group, and delayed progression towards 
end-stage HF. To date, there are no large randomized clinical trials looking at the use of 
oxfenicine in HF patients, and this is perhaps due to the finding by Wang and colleagues that 
identified increases in LV internal resistance and impedance in the LV outflow tract, which 
worsened LV contractile function in oxfenicine-treated diabetic cardiomyopathic rat hearts, 
and increased plasma free FA toxicity (Wang, et al., 2013).  
 
Perhexiline is a potent and reversible inhibitor of CPT1, originally used to treat angina in the 
1970s (Ashrafian, Horowitz et al., 2007). The anti-anginal properties of perhexiline have 
been well-documented in early clinical trials (Cole, et al., 1990; Horowitz, et al., 1986) as 
well as its superior efficacy compared to propranolol (Armstrong, 1973).  Such trials led to 
an increase in the use of perhexiline as an anti-ischemic agent up until the 1980s, when a 
range of adverse effects with perhexiline treatment became apparent, spanning from 
lethargy and nausea to severe neuro- and hepatotoxicity (Shah, et al., 1982). It was later 
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established that perhexiline toxicity is due to prolonged exposure to high plasma levels, and 
was mainly seen in ‘slow hydroxylators’ (due to polymorphic variation of the P450 2D6 
[CYP2D6] enzyme; Morgan, et al., 1984). With this clearer understanding of perhexiline 
pharmacokinetics and pharmacodynamics, it was identified that toxicity could be avoided by 
maintaining perhexiline plasma levels between 0.15 and 0.60 μg/mL (Horowitz, et al., 1986). 
Perhexiline also inhibits the cardiac isoform of CPT1 at a lower plasma concentration than 
the liver isoform, which allows for use of a lower dose to minimize adverse effects 
(Kennedy, et al., 1996). Dose-titration for perhexiline is also necessitated by the potential 
for metabolic drug-drug interactions and ultra-rapid metabolism in some patients (Davies, 
et al., 2004).  
 
Both experimental and clinical investigations into the use of perhexiline as a therapeutic 
agent have since continued, employing close monitoring of plasma levels, and in a recent 
audit of 170 patients who had been on a perhexiline treatment regimen for up to 50 
months, there were no signs of hepatotoxicity (Phuong, et al., 2016). In an open-chest 
canine model, perhexiline treatment was associated with an increase in LV mechanical 
efficiency, increased coronary blood flow, and a reduction in myocardial oxygen 
consumption, all of which were not achieved with GTN infusion alone (Ono, et al., 1982). A 
recent study by Gehmlich and colleagues revealed that perhexiline partially improved 
markers of LV hypertrophy following a 6 week intervention in mice with HCM, and was 
accompanied by a reduction in FA β-oxidation and an increase in glucose utilization 
(Gehmlich, et al., 2015). Yin and colleagues also identified a potentiation of glucose 
oxidation with perhexiline therapy, via an increase in PDH dephosphorylation (signifying an 
increase in PDH activity), in mice fed perhexiline for 4 weeks (Yin, Dwyer et al., 2013). 
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Perhexiline treatment also attenuated cardiac dysfunction caused by energy depletion and 
oxidative stress in mice with induced irreversible HF (Stapel, et al., 2016). 
 
Translational trials in humans have also shown beneficial effects. Unger and co-workers 
demonstrated in a study of elderly patients with inoperable aortic stenosis, that perhexiline 
therapy provided symptomatic relief, improving NYHA functional class (Unger, et al., 1997). 
In a double-blind randomized placebo controlled trial by our group, perhexiline treatment in 
patients with HFrEF significantly improved EF (24% to 34%, P<0.001) and peak exercise 
oxygen consumption (Peak VO2 16.1 ± 0.6 vs 18.8 ± 1.1 ml
.kg-1.min-1, P<0.001) (Lee, et al., 
2005). In another clinical study by our group, perhexiline improved myocardial energetic 
status (improved PCr/ATP ratio; from 1.3 to 1.7; P=0.03), NYHA class (P<0.001), and 
corrected diastolic dysfunction in symptomatic non-obstructive HCM patients (Abozguia, et 
al., 2010).  
 
In a recent randomized controlled trial, short-term treatment with perhexiline in patients 
with non-ischemic HFrEF caused a 30% increase in PCr/ATP ratio (from 1.2 to 1.5; P<0.001) 
and an improvement in NYHA status (Beadle, et al., 2015). However, this study found no 
change in cardiac substrate utilization despite these clear beneficial effects on energetic 
status, suggesting an alternative mechanism of action rather than CPT1 inhibition, at least 
with short term administration. Similarly, in the isolated rat heart models by Kennedy et al 
(2000) and Unger et al (2005), perhexiline perfusion did not alter FA oxidation or CPT1 
activity (Kennedy, et al., 2000; Unger, et al., 2005), despite markedly increasing LV 
mechanical efficiency. 
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Additional effects of perhexiline include blockade of the NAD(P)H oxidase 2 (Nox2) complex, 
conveying beneficial anti-inflammatory effects (Gatto, et al., 2013; Kennedy, et al., 2006; 
Liberts, et al., 2007), and reduced expression of TXNIP  (Ngo, et al., 2011). Moreover, a 
recent study reports that perhexiline activates Krüppel-like factor 14 (KLF14), which 
regulates lipid metabolism, reducing atherosclerotic lesion development in a mouse model 
(Guo, et al., 2015). However, perhexiline has also been shown to inhibit the mammalian 
target of rapamycin complex 1 (mTORC1; Balgi, et al., 2009), an effect which is shared by 
amiodarone. The mTOR-signaling pathway relays signals of adequate energy supplies to 
inhibit cardiomyocyte autophagy, which is over-activated (due to AMPK activation, which 
inhibits mTOR; Matsui, et al., 2007) and maladaptive in the hypertrophic failing heart (De 
Meyer, et al., 2010). This ancillary property of perhexiline is likely to affect the careful 
balance of cardiac autophagy and therefore disease progression and prognosis in HF, 
however further investigation is needed to test this.  
 
4.2 Partial fatty acid oxidation inhibition 
Partial FA oxidation inhibitors inhibit FA metabolism via mechanisms other than CPT1 
inhibition and therefore do not completely block the uptake and use of FAs (Chong, et al., 
2016). Well-investigated agents include trimetazidine and ranolazine, both of which have 
been established for use as prophylactic anti-anginal agents (Lee, et al., 2004). Trimetazidine 
works by inhibiting the LC 3-KAT enzyme of the β-oxidation pathway (Kantor, et al., 2000), 
but also has weak inhibitory effects on CPT1 (Lee, et al., 2004). An experimental study in 
mice with diabetic cardiomyopathy demonstrated improvements in both systolic and 
diastolic function following trimetazidine treatment, as well as a reduction in ROS and 
improvement in cardiac energetic status (Li, et al., 2010). Clinical studies in man have also 
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supported the beneficial effects of trimetazidine. Fragasso and colleagues observed a 
significant improvement in NYHA functional class in patients with HF, an increase in EF 
(36±7% vs 43±10%; P=0.002), and a decrease in LV end-systolic volume (98 ± 1.36 ml vs 81 ± 
27 ml; P=0.04) when compared to the untreated group (Fragasso, et al., 2006). Moreover, in 
a clinical study by Tuunanen et al (2008) involving patients with idiopathic DCM and HFrEF, 
trimetazidine increased EF (from 30.9 ± 8.5% to 34.8 ± 12%; P=0.027) with observed 
increases in cardiac glucose oxidation (Tuunanen, et al., 2008). A meta-analysis by Zhang et 
al (2012) confirmed these therapeutic effects by assessing data collected from 16 RCTs 
involving over 800 chronic HF patients (Zhang, et al., 2012). They found that the use of 
trimetazidine reduced hospitalization, improved symptoms and NYHA functional class, 
increased EF, and ameliorated LV remodeling. In patients with coronary ‘slow flow’, 
trimetazidine also significantly improved LV diastolic function (Suner & Cetin, 2016). 
Although adverse effects with trimetazidine are rare, potential side effects include 
Parkinsonian symptoms (tremor, bradykinesia, and hypertonia) and gait disorders (coupled 
with disequilibrium), however the mechanism for these symptoms has not yet been defined 
(Marti Masso, et al., 2005).   
 
Ranolazine is a similar compound to trimetazidine, which has partial LC 3-KAT inhibiting 
properties and can stimulate glucose oxidation (although there is controversy regarding the 
significance of these effects at therapeutic concentrations; Beadle & Frenneaux, 2010). 
Additionally, it is an inhibitor of the slow inward sodium channel that is activated during 
ischemia and in HF, resulting in an increase in intracellular sodium and thereby, via the 
sodium-calcium exchanger, leads to increased intracellular calcium. This results in action 
potential prolongation and improved diastolic filling. However, it is important to note that 
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increased calcium-signaling within the myocardium has a high ATP-cost in the failing heart. 
Rarely, ranolazine (as a cationic amphiphilic drug) may induce renal phospholipidosis in 
some patients (Scheurle, et al., 2014). The drug has significant anti-anginal effects such as 
increasing time to angina, reducing the number of weekly anginal episode and increasing 
exercise duration (Chaitman, et al., 2004). In a recent study by Zou and colleagues (2016) 
ranolazine restored mitochondrial function, prevented oxidative stress, and inhibited 
apoptosis in a rat model of atrial fibrillation (Zou, et al., 2016).  In another recent study, rats 
were subjected to chronic ischemic HF by left anterior descending artery ligation (Feng, et 
al., 2016). Ranolazine treatment in these rats attenuated brain natriuretic peptide (BNP) 
levels and improved LV function. Furthermore, in a study of rats fed a high salt diet to 
induce hypertension, ranolazine therapy reduced oxidative stress and attenuated diastolic 
dysfunction (De Angelis, et al., 2016). Importantly, a 30-minute ranolazine infusion in 
patients with HFpEF reduced LVEDP in the RALI-DHF study (Maier, et al., 2013). In another 
study by Murray and Colombo, up to 70% of patients with HFrEF showed an improvement in 
EF when treated with ranolazine, compared to no improvement in the noradrenaline 
treatment arm (Murray & Colombo, 2014). 
 
4.3 Malonyl-CoA decarboxylase inhibitors 
The MCD enzyme converts malonyl-CoA into acetyl CoA in the cytosol. MCD inhibition 
increases malonyl-CoA which is a natural inhibitor of the CPT1 enzyme and therefore 
reduces long chain free FA transport into the mitochondria (Fillmore & Lopaschuk, 2013).  
MCD inhibition also increases cardiac carbohydrate oxidation by increasing PDH activity (due 
to reduced allosteric inhibition from acetyl-CoA generated from FA oxidation and lower 
cytosolic citrate levels, i.e. the Randle cycle) and increases insulin sensitivity (Cheng, et al., 
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2006). In an experimental study by Wu and colleagues, MCD inhibition was achieved via 
MCD myocardial gene silencing in rats. Cardiac contractile function measured sixteen weeks 
after the induction of myocardial infarction demonstrated attenuation in post-MI 
dysfunction in the treatment group when compared to the control group, with an 8% 
decrease in EF vs. a 16% decrease in EF, respectively (Wu, et al., 2014). High energy 
phosphate (PCr and ATP) levels were also increased in the left ventricle of the group with 
MCD gene silencing, without lipid toxicity. In a porcine ischemic HF model, the use of novel 
MCD inhibitors significantly increased glucose oxidation which was accompanied by 
significant increases in cardiac performance (Dyck, et al., 2004). In a mouse coronary artery 
ligation induced HF model, MCD knockout mice had a 31% higher EF in comparison to their 
wild-type litter mates and a greater rate of ATP production (Masoud, et al., 2014). To date 
there are no clinical studies assessing the use of MCD inhibition in humans, however the 
experimental evidence in animal models of ischemic heart disease and HF have shown 
promise, and in theory, this method of indirect CPT1 inhibition should provide similar 
beneficial effects to direct CPT1 inhibition. MCD inhibition therefore provides a novel and 
useful mechanism by which cardiac metabolism can be improved and requires further 
clinical investigation to determine whether these beneficial effects translate to HF patients.  
 
4.4 Increased fatty acid utilization 
Despite the success of FA metabolic inhibition in HF to increase glucose oxidation, some 
groups have instead focused on increasing FA utilization (oxidation). Kolwicz and colleagues 
subjected mice with cardiac-specific deletion of ACC (the enzyme that produces malonyl 
CoA from acetyl CoA, and which is a target of AMPK), to TAC to induce HF (Kolwicz, et al., 
2012). They reported a preservation of myocardial energetics and a reduction in both 
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cardiac hypertrophy and fibrosis following TAC in the knock-in mice compared to wild-type 
mice. Furthermore, analysis of isolated hearts from these ACC2-TAC mice revealed that 
glycolytic activity was reduced with no indication of changes in glucose oxidation, thereby 
suggesting improved coupling of glycolysis and glucose oxidation. Chess and colleagues 
investigated the effects of a high-fat diet on mice subjected to TAC (Chess, et al., 2009). The 
authors reported that the high-fat diet did not worsen cardiac hypertrophy or LV 
enlargement but did prevent the decline in the activity of mitochondrial oxidative enzymes 
when compared to TAC mice on a low-fat diet.  
 
Increasing FA metabolism via activation of FA transcription regulators, such as PPARα via the 
use of fibrates, has also been used in an attempt to ameliorate HF (Sarma, et al., 2012). 
PPARγ agonists (such as thiazolidinediones) however, are contraindicated in diabetic 
patients with symptoms of advance HF, due to the increased incidence of worsening 
oedema in these patients in both monotherapy and combination therapy trials for glycaemic 
control (Nesto, et al., 2003). The PPARα activator GW7647 prevented the decline in EF and 
increased cardiac FA β-oxidation in rabbits with volume-overload hypertrophy (Lam, et al., 
2015). The PPARα agonist fenofibrate, has also been shown to reduce serum BNP levels and 
mitochondrial ROS production in rats with isoproterenol-induced HF (Li, et al., 2015). In 
canines with LV pacing-induced HF, chronic treatment with fenofibrate prevented the 
reduction in FA oxidation observed in the untreated group whilst also causing modest 
improvements in cardiac function (Labinskyy, et al., 2007). Fenofibrate treatment has also 
been found to have beneficial effects on endothelial function in patients with advanced 
systolic HF (Yin, Chen et al., 2013) and symptomatic chronic HF (Huang, et al., 2009). 
Gemfibrozil has been reported to attenuate cardiac hypertrophy and oxidative stress in rats 
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subjected to abdominal aortic constriction (Singh, et al., 2015). Selective PPARβ/δ agonists 
have also been shown to have beneficial cytoprotective effects in rat cardiomyocytes 
subjected to oxidative stress (Barlaka, et al., 2015). To date there are no clinical trials that 
have studied PPARα agonists as specific metabolic therapies in HF. Activators of the PPAR 
regulator SIRT-1 however, such as resveratrol (which also activates AMPK by inhibiting ATP 
synthase; Price, et al., 2012), have been tested in the pre-clinical setting and were found to 
reduce oxidative stress in failing hamster hearts (Tanno, et al., 2010) and improve cardiac 
function in rats subjected to arterial ligation (Gu, et al., 2014). It has been identified 
however, that overexpression of SIRT-1 can impair diastolic function and in fact may cause 
DCM (Kawashima, et al., 2011). These studies suggest that increasing FA levels and 
metabolism in HF may help to preserve mitochondrial oxidative capacity. 
 
4.5 Glucose-Insulin-Potassium (GIK) infusion 
Infusion of Glucose-Insulin-Potassium (GIK) increases plasma glucose and cellular glucose 
uptake, whilst reducing lipolysis and lowering plasma free FAs, which by the Randle cycle, 
increases carbohydrate oxidation (Beadle & Frenneaux, 2010). Insulin also activates the 
phosphatidylinositol 3-kinase (PI3K)-Akt-eNOS pathway, increasing myocardial NO (which is 
deficient in HF) and has known cytoprotective effects (Yao, et al., 2014). Through these 
mechanisms myocardial oxygen consumption and ROS accumulation are decreased, 
improving overall myocardial energetics (Cave, et al., 2000). Our group has also shown that 
GIK therapy in addition to standard myocardial protection, in >200 patients undergoing 
cardiac surgery for critical aortic stenosis with significant LV hypertrophy, was associated 
with a lower incidence of low cardiac output syndrome (with a reduction in inotrope use in 
the early postoperative period) compared to the control arm (Howell, et al., 2011). 
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Mechanistically, we showed that GIK resulted in increased AMPK and Akt phosphorylation, 
and post-translational O-linked β-N-acetylglucosamination of cytoprotective myocardial 
proteins in LV biopsies from treated patients. A recent study by Worthley et al. (2007), 
demonstrated a mechanistic basis for beneficial effects with intensive insulin administration 
in 76 hyperglycemic diabetic patients following acute coronary syndromes (ACS). The 
authors showed reduced NO bioavailability in these patients (due to consumption of NO by 
superoxide), which led to impaired platelet responsiveness to its anti-aggregatory effects, 
and that this was reversed with the intervention (Worthley, et al., 2007). In a meta-analysis 
conducted by Fath-Ordoubadi and Beatt (1997), 9 randomized trials in which GIK therapy 
was used for the treatment of acute myocardial infarction (AMI) were collated and reviewed 
(Fath-Ordoubadi & Beatt, 1997). This meta-analysis revealed that in-hospital mortality was 
reduced following GIK therapy in these patients, when compared to placebo (16% vs 21%; 
P=0.004). However, in a more recent meta-analysis, no difference in mortality between the 
treated and untreated groups was found (Mamas, et al., 2010). In addition, the large-scale 
clinical trial, CREATE-ECLA, involving 20,201 patients with acute ST-segment elevation 
myocardial infarction (STEMI), revealed that GIK infusion had no significant effects on the 
rate of cardiac arrest, cardiogenic shock or mortality (Mehta, et al., 2005). This lack of effect 
on mortality was consistent between patients with and without HF as well as with and 
without diabetes. It appears therefore, that GIK may be most beneficial in the diabetic 
cohort of patients with ACS, however this may not translate to a reduction in mortality in 
excess of contemporary therapies for ACS.   
 
Recent clinical investigations have been conducted to specifically assess the use of GIK in 
the chronic HF setting (Kalay, et al., 2008; Nicolas-Robin, et al., 2008). Kalay and colleagues 
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(2008) treated 33 patients with HFrEF due to ischemic cardiomyopathy with GIK and 
analysed cardiac function and BNP levels. The authors observed an improvement in EF (from 
29.2 ± 10.3% to 40.8 ± 10.8%; P=0.001) following 1 week in the treatment group, and a 
significantly lower plasma BNP compared to the placebo group. Similarly, Nicolas-Robin and 
colleagues (2008) investigated the effects of GIK infusion in severe HF following brain death. 
They found that GIK treatment was effective at increasing EF (37 ± 8 vs 21 ± 6%, P<0.0001), 
without significantly altering blood pressure or heart rate.  
 
4.6 GLP-1 Analogues 
Glucagon-like peptide-1 (GLP-1) analogues, such as Exenatide, are commonly used for the 
treatment of type 2 diabetes mellitus for glycaemic control, and have also been shown to 
improve β-cell function and reduce body weight in these patients (Madsbad, et al., 2004; 
Zander, et al., 2002). Previous studies have demonstrated that GLP-1 infusion has beneficial 
effects on cardiovascular function in conjunction with its anti-diabetic properties by 
improving EF, NYHA functional status and peak exercise oxygen consumption (Sokos, et al., 
2006; Wroge & Williams, 2016). GLP-1 analogue infusion following AMI has also been shown 
to have cardioprotective benefits, likely from activation of the PI3K-Akt pathway and 
through increasing cytosolic cAMP, which inhibit the mitochondrial permeability transition 
pore (mPTP), and increase myocardial expression of PPAR-β/δ, nuclear factor related factor 
2 (Nrf-2), and haemoxygenase-1 (HO-1; Giblett, et al., 2016). Liraglutide therapy has also 
been shown to increase plasma ANP levels due to atrial GLP-1 receptor activation, which has 
potent natriuretic and antihypertensive effects via increased vascular cGMP (Kim, et al., 
2013). In both rat and mouse models of HF, exenatide treatment delayed the progression 
towards HF and increased survival rates following AMI (Wroge & Williams, 2016). 
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Furthermore, Nathanson and colleagues demonstrated that intravenous infusion of 
Exenatide, in patients with type 2 diabetes and HF, increased cardiac index (CI) and reduced 
PCWP (Nathanson, et al., 2012).  
 
4.7 Dichloroacetate (DCA)  
The pyruvate analogue DCA is an inhibitor of PDH kinase, which phosphorylates and inhibits 
PDH. Therefore DCA increases PDH activity and carbohydrate oxidation (Fillmore & 
Lopaschuk, 2013). DCA is an effective treatment for lactic acidosis by directing pyruvate 
conversion away from lactate and towards acetyl-CoA. As PDH activity is reduced in HF, DCA 
has been suggested as a potential treatment strategy (Lewis, et al., 1998). In a high salt diet-
induced HF model in rats, DCA treatment was found to increase glucose uptake, improve 
cardiac function by reducing progression to HF, and improve overall survival (Kato, et al., 
2010). Furthermore, in a set of in vitro cardiomyocyte studies, DCA was shown by the same 
group to reduce oxidative stress and prevent cell death (Kato, et al., 2010). DCA treatment 
also enhanced mitochondrial metabolism and suppressed apoptotic cell death in a neonatal 
mouse model of hypoxic ischemia (Sun, et al., 2016). In a clinical study by Bersin et al (1994) 
of patients with chronic HF, a 30-minute infusion of DCA increased LV function (increase in 
stroke volume: +5.3 ml/beat; P<0.02; and LV stroke work: +1.8 g/m2/beat; P<0.02) whilst 
also reducing myocardial oxygen consumption (from 19.3 to 16.3 ml/min; P=0.06). In 
addition, LV mechanical efficiency was improved (from 15.2% to 20.6%; P=0.03; Bersin, et 
al., 1994). Importantly however, long term use of DCA may result in peripheral neuropathy 
and this may limit its potential therapeutic applications (Calcutt, et al., 2009).   
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4.8 AMPK activators 
As a key regulator of cellular energy homeostasis, pharmacological activation of AMPK in the 
setting of metabolic syndromes such as HF has been suggested. In particular, indirect 
activators of AMPK such as 5′-aminoimidazole-4-carboxyamide-ribonucleoside (AICAR) and 
the biguanide metformin have shown promise (Kim & Dyck, 2015). As stated, activated 
AMPK increases insulin-independent glucose uptake via GLUTs 1 & 4, increases 
gluconeogenesis and glycolysis (via SIRT1-PGC1α signaling), increases lipolysis and FA 
synthesis, and increases free FA uptake and oxidation (by reducing malonyl CoA levels;   
(Zaha & Young, 2012). AICAR treatment reduced LV hypertrophy in rat cardiomyocytes 
(Chan, et al., 2004) and in pressure-overload mice (Li, et al., 2014). Oxidative stress-induced 
apoptosis and progression of HF were attenuated by metformin therapy in a canine model 
of rapid pacing-induced HF (Sasaki, et al., 2009). The authors observed a reduction in LVEDP, 
attenuated oxidative stress, and slower progression of HF in the treatment arm when 
compared to controls. In mice subjected to left coronary artery occlusion, metformin 
therapy improved survival by 47%, preserved LV structure and EF, and improved 
mitochondrial respiration and ATP production (Gundewar, et al., 2009). In a non-diabetic 
post-infarct rat model of HF, animals treated with metformin had significantly smaller 
infarct sizes, reduced LV cavity dilation, and a preserved EF when compared to untreated 
rats (Yin, et al., 2011). In addition, Xiao and colleagues found that metformin inhibited 
cardiac fibrosis in TAC mice (Xiao, et al., 2010). A retrospective analysis by Eurich et al (2005) 
of patients with HF and type 2 diabetes, demonstrated lower morbidity and mortality 
following metformin treatment (Eurich, et al., 2005). However, a randomized controlled trial 
by the same group in 2009 was abandoned due to significant issues with patient 
recruitment, stemming from the very high rates of metformin prescribing in clinical practice, 
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including those patients in whom metformin is contraindicated (Eurich, et al., 2009). 
However, others have shown that metformin is quite safe in advanced HFrEF (Shah, et al., 
2010), and further clinical studies are warranted.  
 
4.9 Mitochondrial-targeted antioxidants  
Coenzyme Q10 (CoQ10), also known as ubiquinone, plays an essential role in oxidative 
phosphorylation as it forms part of the ETC within the mitochondria. Although an 
endogenous substance, CoQ10 can also be given as a non-prescription nutritional 
supplement, and therefore the use of CoQ10 as a therapeutic treatment for cardiovascular 
disease has been investigated by a broad range of clinical studies (Sharma, Fonarow et al., 
2016).  Levels of CoQ10 tend to decline with age, and deficiency has been associated with 
diseases such as HF. In fact, a close positive correlation between HF severity and severity of 
CoQ10 deficiency has been identified (Oleck & Ventura, 2016). It has been proposed that 
the antioxidant and free radical scavenging properties of CoQ10 are important in 
combatting harmful effects from the high ROS observed in HF patients (Sharma, Fonarow et 
al., 2016). Furthermore, the vital role of CoQ10 in oxidative phosphorylation suggests that 
ATP generation may be directly enhanced via CoQ10 supplementation (Oleck & Ventura, 
2016). 
 
One of the first clinical trials of CoQ10 therapy in patients with HF was carried out in the 
1980s (Langsjoen, et al., 1985). Langsjoen and colleagues (1985) demonstrated, in a study of 
143 patients, an improvement in stroke volume and EF following CQ10 treatment over a 12-
week period. Further studies have confirmed these improvements in cardiac function in HF 
patients, but these have translated to only minimal improvements in mortality (Morisco, et 
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al., 1994; Munkholm, et al., 1999). Many of these trials however, were underpowered to 
assess this end-point, and were performed at a time that coincided with the advent of ACE-
inhibitor and β-blocker therapies, which revolutionized HF treatment and drastically 
improved survival in their own right. A meta-analysis by Sanders and colleagues reviewed 
the data collected from 11 randomized trials dated between 1966 and 2005 (Sander, et al., 
2006). They reported that isolated CoQ10 therapy caused a net 3.7% improvement in EF and 
an increase in CO, thereby improving systolic function in chronic HF, however the 
heterogeneity in ‘standard treatment’ over the course of these studies makes direct 
comparison difficult. The meta-analysis carried out by Fotino et al (2013), also 
demonstrated similar findings, reporting an increase in cardiac performance and 
improvement in NYHA functional class. However the effects on mortality still remain unclear 
(Fotino, et al., 2013). More recently, a randomized controlled trial (Q-SYMBIO), conducted 
with 420 patients with moderate to severe HF, has been completed (Mortensen, et al., 
2014). Patients were given 100 mg CoQ10 three times daily in addition to standard therapy 
for 2 years. The results of the study revealed an improvement in cardiovascular mortality 
(9% vs 16%, P=0.026), and reduced hospital admissions for HF (P=0.033) when compared to 
the placebo group. Furthermore, this study confirmed that long-term treatment with CoQ10 
is safe for use in HF in the context of modern therapies, however larger contemporary RCTs 
assessing the efficacy of CoQ10 in HF are still necessary. 
 
Most ‘conventional’ antioxidants that have been studied in clinical trials achieve low 
mitochondrial concentrations, which may limit their efficacy. However, a number of novel 
antioxidants have been developed that are selectively concentrated in the mitochondria 
because they are lipophilic and negatively charged (Munzel, et al., 2015). Most notable of 
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these are MitoQ and SS31. Developed in the late 1990s, MitoQ consists of CoQ10 
conjugated with the lipophilic compound triphenylphosphonium. This allows it to 
accumulate extensively and selectively within the mitochondria (Bayeva, et al., 2013). MitoQ 
therapy was found to protect cardiac function in a spontaneously hypertensive rat model of 
HF (Graham, et al., 2009) and to reduce mitochondrial oxidative stress and ROS levels in an 
anthracycline-induced model of cardiac failure (Chandran, et al., 2009). A limitation of 
MitoQ therapy and other triphenylphosphonium-conjugated antioxidants however, is that 
their uptake relies upon preservation of the mitochondrial membrane-potential, which may 
be altered in HF (Bayeva, et al., 2013). 
 
SS31 is a tyrosine-containing Szeto-Schiller peptide which selectively accumulates within the 
mitochondria, and is unaffected by membrane potential (Bayeva, et al., 2013). Within the 
mitochondria, SS31 binds to cardiolipin and protects the structure and organization of 
respirasomes, facilitating electron transfer and promoting oxidative phosphorylation (Szeto, 
2014). In a hypertensive mouse model of HF, SS31 treatment attenuated cardiac 
hypertrophy, cardiac fibrosis and diastolic dysfunction (Dai, et al., 2011). Furthermore, in a 
mouse TAC model, SS31 therapy ameliorated cardiac hypertrophy, cardiac fibrosis and 
systolic dysfunction and also abolished mitochondrial oxidative damage (Dai, et al., 2013).  
 
Elamipretide is a tetrapeptide that crosses the outer mitochondrial membrane and, like 
SS31, associates with cardiolipin in the inner mitochondrial membrane, stabilizing it and 
facilitating the maintenance of respirasome organization (Szeto, 2014). A first-in-human 
RCT, involving 118 first-time anterior STEMI patients undergoing successful angioplasty, 
investigated the additive effect of Elamipretide (MTP-131) vs placebo on infarct size, as 
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assessed by the creatine kinase myocardial band (CK-MB) area under the curve over 72h 
(Gibson, et al., 2016). The drug was well tolerated, however the results did not reach 
significance compared to the placebo group. In a recent study using a canine micro-
embolization model of HF, elamipretide administered for 3 months was associated with 
higher LVEF and reduced plasma BNP when compared to placebo (Sabbah, et al., 2016). 
Furthermore, elamipretide increased mitochondrial membrane potential, rate of ATP 
synthesis, and reduced mitochondrial ROS generation. Phase 2 studies investigating the 
effects of Elamipretide in patients with HF are ongoing (NCT02788747; NCT02814097).  
 
As previously stated, increased ROS in HF inhibits cytosolic CK activity and thereby impairs 
energy transfer from the mitochondria to the site of utilization in the cytosol (Rosca & 
Hoppel, 2013). As such, increasing CK flux via the inhibition of superoxide generation by the 
xanthine oxidoreductase enzyme (an important source of mitochondrial ROS) has been 
suggested as a potential therapeutic strategy in HF (Gavin & Struthers, 2005). A small and 
recent randomized trial, of 16 non-ischemic HFrEF patients, demonstrated increased 
myocardial CK flux following intravenous allopurinol therapy in parallel with increased 
cytosolic CK activity (Hirsch, et al., 2012).  
 
5. Conclusion  
Cardiac energetic impairment plays an important role in the pathophysiology of both HFrEF 
and HFpEF. Pharmacotherapeutic agents that reduce FA oxidation and increase glucose 
oxidation improve energy generation and show promise for the treatment of HF. Other 
agents that target mitochondrial oxidative stress are also being investigated. With this in 
mind, shifting the focus of new pharmacotherapies away from neurohormonal treatments 
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and towards metabolic modulation may help us to re-energize our efforts to improve 
mortality and quality of life for sufferers of this malignant disease.  
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Fig 1:  
 
Fig 1: An Overview of Cardiac Metabolism in the Healthy Heart 
Fatty acids and glucose are both key substrates of cardiac metabolism. Through various 
enzymatic pathways these substrates generate high levels of adenosine triphosphate (ATP) 
within the mitochondria of a heathy heart. ATP generation is essential in order to fuel 
continuous cardiac function. 
ADP, adenosine diphosphate; ATP, adenosine triphosphate; CoA, coenzyme A; CPT, carnitine 
palmitoyltransferase; ETC, electron transport chain; FADH2, flavin adenine dinucleotide; 
FAT, fatty acid translocase; GLUT, glucose transporter; H+, hydrogen ion; PCr, 
phosphocreatine; Pi, inorganic phosphate; PDH, pyruvate dehydrogenase; TCA, tricarboxylic 
acid; ROS, reactive oxygen species. 
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Fig 2:  
 
Fig 2: An Overview of Cardiac Metabolism in the Failing Heart and Targets of Metabolic 
Modulators 
Severe disturbances in cardiac metabolism decrease adenosine triphosphate (ATP) 
production in heart failure, including decreased fatty acid (FA) and glucose oxidation, and 
high reactive oxygen species (ROS) levels. Many drugs that modulate cardiac metabolism 
have been identified and differ in their mechanisms to restore cardiac energetic production. 
ADP, adenosine diphosphate; ATP, adenosine triphosphate; CoA, coenzyme A; CoQ10, 
coenzyme Q10; CPT, carnitine palmitoyltransferase; DCA, dichloroacetate; ETC, electron 
transport chain; FADH2, flavin adenine dinucleotide; FAT, fatty acid translocase; GIK, 
Glucose-Insulin-Potassium; GLUT, glucose transporter; H+, hydrogen ion; MCD, malonyl-CoA 
decarboxylase; PCr, phosphocreatine; Pi, inorganic phosphate; PDH, pyruvate 
dehydrogenase; TCA, tricarboxylic acid; ROS, reactive oxygen species.  
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Table 1: Metabolic modulator clinical status 
 
 
Key metabolic modulators that have been proposed for use as novel treatments for heart 
failure and their associated metabolic action and clinical status. 
 
AMPK, adenosine monophosphate-activated protein kinase; ATP, adenosine triphosphate; 
BNP, brain natriuretic peptide; CPT1, carnitine palmitoyltransferase 1; ETC, electron 
transport chain; GLP-1, glucagon-like-peptide-1; HPAECs, human pulmonary artery 
endothelial cells; LC 3-KAT, long-chain 3-ketoacyl-CoA thiolase; LV, left ventricular; LVEF, left 
ventricular ejection fraction; NYHA, New York Heart Association; PBMCs, peripheral blood 
mononuclear cells; PCWP, pulmonary capillary wedge pressure; PDK, pyruvate 
dehydrogenase kinase; PPARα, peroxisome proliferator-activated receptor α; ROS, reactive 
oxygen species; SIRT1, Sirtuin 1. 
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Metabolic agent Drug class 
Key metabolic 
mechanism 
FDA status 
Stage of development as 
metabolic modulator in HF 
Key results Key references 
Etomoxir 
Irreversible CPT1 
inhibitor 
Fatty acid oxidation 
inhibition  
Withdrawn from clinical use due to severe 
hepatotoxicity 
Increase in LVEF and CO following 
exercise vs placebo (P<0.01) 
Schmidt-Schweda and 
Holubarsch, 2000, 
Holubarsch et al., 2007 
Oxfenicine 
Irreversible CPT1 
inhibitor 
Fatty acid oxidation 
inhibition 
Pre-clinical data only 
Canine rapid pacing HF: 
Reduction in LV dilatation and 
hemodynamic alternations vs placebo 
(P<0.05) 
Lionetti et al., 2005 
Amiodarone 
Class III anti-
arrhythmic;  
CPT1 inhibitor 
Fatty acid oxidation 
inhibition 
FDA approved 
Ventricular 
arrhythmias 
Phase II 
Reduction in non-sustained ventricular 
tachycardia (P=0.06)and increase in LVEF 
(P<0.01) 
 
Suppressed ventricular arrhythmias and 
increased LVEF vs placebo (P<0.001) 
Hammer et al., 1989 
 
 
 
Singh et al., 1995 
Perhexiline 
Reversible CPT1 
inhibitor 
Fatty acid oxidation 
inhibition 
FDA approved 
Refractory angina 
Phase II 
30% increase in PCr/ATP ratio (P<0.01) 
Improvement in NYHA functional class vs 
placebo (P=0.036) 
 
Improvement in peak exercise oxygen 
consumption (P<0.001), quality of life 
(P=0.04) and LVEF (P<0.001) 
Beadle et al., 2015 
 
 
 
Lee et al., 2005 
Trimetazidine 
LC 3-KAT inhibitor 
Weak CPT1 inhibitor 
Fatty acid oxidation 
inhibition 
FDA approved 
Angina 
Phase II 
Increase in LVEF (P=0.002), improvement 
in NYHA functional class (P<0.0001) 
Fragasso et al., 2006 
Ranolazine 
Partial LC 3-KAT 
inhibitor 
Fatty acid oxidation 
inhibition 
FDA approved 
Angina 
Phase II 
Reduced LV end-diastolic pressure and 
PCWP vs placebo (P=0.04) 
 
Increase in LVEF in HFrEF patients 
(P=0.001) and HFpEF patients (P=0.003) 
vs placebo 
Maier et al., 2013 
 
 
Murray and Colombo, 
2014 
Malonyl-CoA 
decarboxylase 
gene silencer 
Malonyl-CoA 
decarboxylase 
inhibitor  
Fatty acid oxidation 
inhibition 
Pre-clinical data only 
Coronary artery ligated mice: 
31% higher LVEF in MCD knock-out vs 
wild-type mice 
Increase in ATP production (P<0.05) 
Masoud et al., 2014 
Fenofibrate PPARα agonist 
Fatty acid oxidation 
stimulation 
FDA approved 
hypercholesterolemia 
Pre-clinical data only 
Cultured HPAECs from HFrEF patients: 
Improved endothelial function vs control 
(P<0.05) 
 
Isolated PBMCs from HF patients: 
Improved endothelial function vs control 
Yin, Chen et al., 2013 
 
 
 
Huang et al., 2009 
56 
(P=0.0121) 
Gemfibrozil PPARα agonist 
Fatty acid oxidation 
stimulation 
FDA approved 
hypercholesterolemia 
Pre-clinical data only 
Abdominal aortic constricted rats: 
Reduced oxidative stress and 
hypertrophy (P<0.05) 
Singh et al., 2014a 
 
Resveratrol SIRT1 activator 
Fatty acid oxidation 
stimulation; 
Mitochondrial ROS 
scavenging 
FDA approved 
As dietary supplement 
Pre-clinical data only 
Mouse myoblast cell-line: 
Increased resistance to oxidative stress 
(P<0.05) 
 
Cardiomyocytes from failing hamster 
hearts: 
Suppressed fibrosis, preserved cardiac 
function, and improved survival (P<0.05) 
Tanno et al., 2010 
 
 
 
Gu et al., 2014 
GIK infusion Glucose and insulin  
Increases glucose 
oxidation 
FDA approved 
Type 2 diabetes 
mellitus 
Ischemic heart disease 
Phase II 
Increase in LVEF 1 week (P=0.001) and 1  
month (P=0.01) post-treatment, reduced 
BNP (P=0.01) vs placebo 
 
Increase in LVEF (P<0.0001) 
Kalay et al., 2008 
 
 
 
Nicolas-Robin et al., 2008 
Exenatide GLP-1 agonist 
Increases insulin 
release;  
Glucose oxidation 
stimulation 
FDA approved 
Type 2 diabetes 
mellitus 
Phase II 
Increased cardiac index (P=0.003) and 
improved PCWP (P=0.001) 
Nathanson et al., 2012 
Dichloroacetate 
PDK inhibitor 
(pyruvate analogue) 
Glucose oxidation 
stimulation 
/ Phase II 
Improved left ventricular mechanical 
efficiency  (P=0.03) and reduction in 
myocardial oxygen consumption 
(P=0.06) 
Bersin et al., 1994 
Metformin 
Biguanide oral 
hypoglycaemic agent; 
Indirect AMPK 
activation 
Glucose oxidation 
stimulation 
FDA approved 
Type 2 diabetes 
mellitus 
Pre-clinical data only  
Phase II trial aborted 
Canine rapid pacing HF: 
Reduced LV end-diastolic pressure and 
PCWP, reduced BNP expression (P<0.05) 
 
Reduced cardiac fibrosis (P<0.01)and 
improved LV end-diastolic pressure 
(P<0.05) 
 
Trial aborted due to patient recruitment  
as they were on therapies that were 
contraindicated 
Sasaki et al., 2009 
 
 
 
Xiao et al., 2010 
 
 
 
Eurich et al., 2009 
 
 
 
Coenzyme Q10 
Important component 
of ETC; Antioxidant 
Mitochondrial ROS 
scavenging 
FDA approved 
As dietary supplement 
Phase II 
Reduced cardiovascular mortality 
(P=0.026), all-cause mortality (P=0.018) 
and hospital stay (P=0.033) vs placebo. 
Mortensen et al., 2014 
57 
Improvement in NYHA functional class ( 
P=0.028) after 2 years 
MitoQ 
Selective 
mitochondria-targeted 
antioxidant 
Mitochondrial ROS 
scavenging 
FDA approved 
As dietary supplement 
Pre-clinical data only 
Spontaneously hypertensive rats: 
Reduced hypertrophy (P=0.002) and 
reduced systolic blood pressure 
(P=0.0001)and improved endothelial 
function vs control 
Graham et al., 2009 
SS31 
Selective 
mitochondria-targeted 
antioxidant 
Cardiolipin 
stabilization; 
Mitochondrial ROS 
scavenging 
/ Pre-clinical data only 
Transverse aortic constricted mice: 
Reduced hypertrophy (P<0.05), fibrosis 
(P=0.005) and abolished mitochondrial 
oxidative damage (P<0.05) vs control 
Dai et al., 2013 
Elamipretide 
Selective 
mitochondria-targeted 
antioxidant 
Cardiolipin 
stabilization; 
Cardiolipin peroxidase 
inhibition 
/ 
Pre-clinical data only – 
Phase II trials commenced 
Canine microembolization-induced HF: 
Increase in LVEF (P<0.05), reduced 
plasma BNP (P<0.001)and increased 
ATP/ADP ratio (P<0.001) vs placebo 
Sabbah et al., 2016 
 
NCT02788747 
NCT02814097 
Allopurinol 
Xanthine oxidase 
inhibitor 
 
Mitochondrial ROS 
scavenging 
FDA approved 
For hyperuricemia 
Phase II 
Increased cardiac PCr/ATP ratio (P<0.02) 
and mean CK flux (P<0.007) vs placebo 
Hirsch et al., 2012 
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